The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
Abstract
Purpose: The AVAGAST study showed that adding bevacizumab to chemotherapy in patients with advanced gastric cancer improves progression-free survival and tumor response rate but not overall survival. To examine the hypothesis that angiogenic markers may have predictive value for bevacizumab efficacy in gastric cancer, AVAGAST included a prospective, mandatory biomarker program. Patients and Methods: Patients with previously untreated, locally advanced or metastatic gastric cancer were randomly assigned to bevacizumab (n = 387) or placebo (n = 387) in combination with chemotherapy. Blood and tumor tissue samples were collected at baseline. Prespecified biomarkers included plasma vascular endothelial growth factor-A (VEGF-A), protein expression of neuropilin-1, and VEGF receptors-1 and -2 (VEGFR-1 and VEGFR-2). Correlations between biomarkers and clinical outcomes were assessed by using a Cox proportional hazards model. Results: Plasma was available from 712 patients (92%), and tumor samples were available from 727 patients (94%). Baseline plasma VEGF-A levels and tumor neuropilin-1 expression were identified as potential predictors of bevacizumab efficacy. Patients with high baseline plasma VEGF-A levels showed a trend toward improved overall survival (hazard ratio [HR], 0.72; 95% CI, 0.57 to 0.93) versus patients with low VEGF-A levels (HR, 1.01; 95% CI, 0.77 to 1.31; interaction P = .07). Patients with low baseline expression of neuropilin-1 also showed a trend toward improved overall survival (HR, 0.75; 95% CI, 0.59 to 0.97) versus patients with high neuropilin-1 expression (HR, 1.07; 95% CI, 0.81 to 1.40; interaction P = .06). For both biomarkers, subgroup analyses demonstrated significance only in patients from non-Asian regions. Conclusion: Plasma VEGF-A and tumor neuropilin-1 are strong biomarker candidates for predicting clinical outcome in patients with advanced gastric cancer treated with bevacizumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Self-citationTrastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., Van De Vijver, M., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,187
Ohtsu, A., Shah, M. A., Van Cutsem, E., Rha, S. Y., Sawaki, A., Park, S. R., Lim, H. Y., Yamada, Y., Wu, J., Langer, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2236 · Cited by 1,110
Self-citationSchneider, B. P., Wang, M., Radovich, M., Sledge, G. W., Badve, S., Thor, A., Flockhart, D. A., Hancock, B., Davidson, N., Gralow, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1612 · Cited by 604
HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer
Park, D. I., Yun, J. W., Park, J. H., Oh, S. J., Kim, H. J., Cho, Y. K., Sohn, C. I., Jeon, W. K., Kim, B. I., Yoo, C. H., et al. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-9057-1 · Cited by 329
Begnami, M. D., Fukuda, E., Fregnani, J. H. T. G., Nonogaki, S., MONTAGNINI, A. L., da Costa, W. L., & Soares, F. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.6313 · Cited by 272
Dowlati, A., Gray, R., Sandler, A. B., Schiller, J. H., & Johnson, D. H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1154 · Cited by 263
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
Murukesh, N., Dive, C., & Jayson, G. C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605483 · Cited by 237
Sex Steroid Hormone Receptors in Human Thymoma
Ishibashi, H., Suzuki, T., Suzuki, S., Moriya, T., Kaneko, C., Takizawa, T., Sunamori, M., Handa, M., Kondo, T., & Sasano, H. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021353 · Cited by 211
Kaptain, S., Tan, L. K., & Chen, B. (2001) · Diagnostic Molecular Pathology · doi:10.1097/00019606-200109000-00001 · Cited by 208
Schultheis, A. M., Lurje, G., Rhodes, K. E., Zhang, W., Yang, D., Garcia, A. A., Morgan, R., Gandara, D., Scudder, S., Oza, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0351 · Cited by 182
Role of Class 3 Semaphorins and Their Receptors in Tumor Growth and Angiogenesis
Gaur, P., Bielenberg, D. R., Samuel, S., Bose, D., Zhou, Y., Gray, M. J., Dallas, N. A., Fan, F., Xia, L., Lu, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1810 · Cited by 155
Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
Jubb, A. M., Miller, K. D., Rugo, H. S., Harris, A. L., Chen, D., Reimann, J. D., Cobleigh, M., Schmidt, M., Langmuir, V. K., Hillan, K. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1791 · Cited by 103
Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells
Sasano, H., Date, F., Imatani, A., Asaki, S., & Nagura, H. (1993) · Human Pathology · doi:10.1016/0046-8177(93)90236-a · Cited by 83
New Automated Multiplex Assay for Bone Turnover Markers in Osteoporosis
Claudon, A., Vergnaud, P., Valverde, C., Mayr, A., Klause, U., & Garnero, P. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105866 · Cited by 69
Weickhardt, A. J., Williams, D., Lee, C., Simes, J. R., Murone, C., Wilson, K., Cummins, M. M., Asadi, K., Price, T. J., Mariadason, J. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3531 · Cited by 53
Self-citationBernaards, C. A., Hegde, P., Chen, D. S., Holmgren, E. B., Zheng, M., Jubb, A. M., Koeppen, H., Scherer, S. J., & Chen, D. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.10519 · Cited by 41
Self-citationHolden, S. N., Ryan, E., Kearns, A., Holmgren, E. B., & Hurwitz, H. I. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3555 · Cited by 30
Miles, D. W., de Haas, S., Dirix, L. Y., Chan, A., Pivot, X. B., Tomczak, P., Provencher, L., Delmar, P., & Scherer, S. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-p2-16-04 · Cited by 26
Self-citationNixon, A. B., Pang, H., Starr, M. D., Hollis, D. R., Friedman, P. N., Bertagnolli, M. M., Kindler, H. L., Goldberg, R. M., Venook, A. P., & Hurwitz, H. I. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.10508 · Cited by 12
Liu, Y., Tran, H. T., Lin, Y., Martin, A., Zurita, A. J., Sternberg, C. N., Amado, R. G., Pandite, L. N., Heymach, J. V., & VEG105192 Team (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.4553 · Cited by 10
Cited by
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Self-citationVan Cutsem, E., Sagaert, X., Topal, B., Haustermans, K., & Prenen, H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30354-3 · Cited by 1,793
Self-citationGoel, H. L., & Mercurio, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3627 · Cited by 1,253
Garcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102017 · Cited by 1,159
Li, J., Qin, S., Xu, J., Xiong, J., Wu, C., Bai, Y., Liu, W., Tong, J., Liu, Y., Xu, R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5995 · Cited by 972
Metadata
- Authors
- Van Cutsem, E., de Haas, S., Kang, Y.-K., Ohtsu, A., Tebbutt, N. C., Ming Xu, J., Peng Yong, W., Langer, B., Delmar, P., Scherer, S. J., & Shah, M. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-06-10
- Volume
- 30
- Issue
- 17
- Pages
- 2119-2127
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2109491042
- Cited by
- 477
- References
- 28
- FWCI
- 51.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.